Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.89)
# 287
Out of 4,598 analysts
496
Total ratings
59.7%
Success rate
23%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $70 | $65.47 | +6.92% | 22 | Jul 31, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $709 | $482.00 | +47.10% | 15 | Jul 31, 2026 | |
| INCY Incyte | Reiterated: Hold | n/a | $118.43 | - | 37 | Jul 29, 2026 | |
| ALT Altimmune | Maintained: Buy | n/a | $3.00 | - | 4 | Jul 29, 2026 | |
| EPA: IVA Inventiva S.A. | Reiterated: Buy | n/a | $3.79 | - | 1 | Jul 27, 2026 | |
| IVA Inventiva | Reiterated: Buy | $13 | $4.25 | +205.88% | 5 | Jul 27, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $57 | $27.49 | +107.35% | 3 | Jul 27, 2026 | |
| SRRK Scholar Rock Holding | Maintained: Buy | n/a | $45.85 | - | 30 | Jul 21, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | n/a | $132.28 | - | 23 | Jul 16, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | n/a | $64.41 | - | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,370 | $1,121.36 | +22.17% | 36 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $17 | $7.93 | +114.38% | 10 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 | $34.98 | +22.93% | 6 | Jul 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 | $100.31 | +35.58% | 23 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $38.38 | - | 34 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $9.61 | - | 1 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $5.83 | +105.83% | 12 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.11 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $106 | $76.45 | +38.65% | 37 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $8.06 | +24.07% | 15 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.96 | - | 7 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.15 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $378.87 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $98.45 | +117.37% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $23.22 | -0.95% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $759.24 | +6.95% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $105.37 | -20.28% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.44 | n/a | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $201.82 | n/a | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.20 | n/a | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $127.77 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.03 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $245.10 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.35 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $66.80 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $5.69 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.0001 | n/a | 7 | Mar 20, 2023 |
Bristol-Myers Squibb Company
Jul 31, 2026
Reiterated: Buy
Price Target: $70
Current: $65.47
Upside: +6.92%
Madrigal Pharmaceuticals
Jul 31, 2026
Reiterated: Buy
Price Target: $709
Current: $482.00
Upside: +47.10%
Incyte
Jul 29, 2026
Reiterated: Hold
Price Target: n/a
Current: $118.43
Upside: -
Altimmune
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $3.00
Upside: -
Inventiva S.A.
Jul 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.79
Upside: -
Inventiva
Jul 27, 2026
Reiterated: Buy
Price Target: $13
Current: $4.25
Upside: +205.88%
NewAmsterdam Pharma Company
Jul 27, 2026
Reiterated: Buy
Price Target: $57
Current: $27.49
Upside: +107.35%
Scholar Rock Holding
Jul 21, 2026
Maintained: Buy
Price Target: n/a
Current: $45.85
Upside: -
Protagonist Therapeutics
Jul 16, 2026
Maintained: Buy
Price Target: n/a
Current: $132.28
Upside: -
MBX Biosciences
Jul 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $64.41
Upside: -
Jul 9, 2026
Reiterated: Buy
Price Target: $1,370
Current: $1,121.36
Upside: +22.17%
Jul 2, 2026
Reiterated: Buy
Price Target: $11 → $17
Current: $7.93
Upside: +114.38%
Jul 1, 2026
Reiterated: Buy
Price Target: $43
Current: $34.98
Upside: +22.93%
Jun 29, 2026
Rated: Buy
Price Target: $136
Current: $100.31
Upside: +35.58%
Jun 17, 2026
Maintained: Buy
Price Target: n/a
Current: $38.38
Upside: -
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.61
Upside: -
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $5.83
Upside: +105.83%
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $10.11
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $106
Current: $76.45
Upside: +38.65%
May 1, 2026
Maintained: Hold
Price Target: $10
Current: $8.06
Upside: +24.07%
Apr 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.96
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.15
Upside: -
Nov 5, 2025
Maintained: Hold
Price Target: n/a
Current: $378.87
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $98.45
Upside: +117.37%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $23.22
Upside: -0.95%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $759.24
Upside: +6.95%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $105.37
Upside: -20.28%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.44
Upside: n/a
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $201.82
Upside: n/a
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.20
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $127.77
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $25.03
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $245.10
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $1.35
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $66.80
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $5.69
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.0001
Upside: n/a